![](/img/cover-not-exists.png)
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Schöffski, Patrick, Wozniak, Agnieszka, Escudier, Bernard, Rutkowski, Piotr, Anthoney, Alan, Bauer, Sebastian, Sufliarsky, Jozef, van Herpen, Carla, Lindner, Lars H., Grünwald, Viktor, Zakotnik, BrankVolume:
87
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2017.10.014
Date:
December, 2017
File:
PDF, 2.55 MB
english, 2017